



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RECEIPT OF NO OBJECTION FROM THE SINGAPORE EXCHANGE REGULATION (“SGX REGCO”) FOR THE COMPANY’S APPLICATION FOR EXTENSION OF TIME:

- A. TO ANNOUNCE THE COMPANY’S UNAUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2024 (“FY2024”) (“FY2024 RESULTS”);
- B. TO HOLD THE COMPANY’S ANNUAL GENERAL MEETING (“AGM”) FOR FY2024; AND
- C. TO ISSUE THE COMPANY’S ANNUAL REPORT FOR FY2024 (“AR2024”)

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcement (as defined below).

The Board of Directors (the “**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) refers to the Company’s announcement dated 16 August 2024 (the “**Announcement**”) in relation to the Company’s application to the SGX RegCo for the Extensions, in relation to the following:

- (a) 2-month extension of time for the Company to release its FY2024 Results by 29 October 2024 (from the current deadline of 29 August 2024 prescribed under Rule 705(1) of the Section B: Rules of Catalist of the Listing Manual of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) (“**Catalist Rules**”));
- (b) 2-month extension of time for the Company to convene its AGM for FY2024 by 31 December 2024 (from the current deadline of 31 October 2024 prescribed under Rule 707(1) of the Catalist Rules); and
- (c) 2-month extension of time for the Company to issue the AR2024 by 16 December 2024, being at least 14 days before the date of its AGM (from the current deadline of 16 October 2024 prescribed under Rule 707(2) of the Catalist Rules),

(collectively, “**Extensions**”).

Grant of Extension of Time

The Board wishes to inform that the SGX RegCo has on 17 September 2024 informed the Company that it has no objection to the Extensions (the “**Waiver**”), subject to the following:

- (i) the Company announcing the Waiver granted, the reasons for seeking the Waiver, the conditions as required under Rule 106 of the Catalist Rules and if the Waiver conditions have been satisfied. If the Waiver conditions have not been met on the date of the announcement, the Company must make an update announcement when the conditions have all been met;
- (ii) submission of a written confirmation from the Company that it is not aware of any information that will have a material bearing on investors’ decision which has yet to be announced by the Company;

- (iii) submission of the Board of Directors' confirmation that the Waiver will not be in contravention of any laws and regulations governing the Company and its constitution;
- (iv) the Company convening its AGM for FY2024 by 31 December 2024;
- (v) the Company making an immediate disclosure via SGXNet if it is/will be in contravention of any laws and regulations governing the Company and the constitution of the Company (or the equivalent in the Company's country of incorporation) arising from the Waiver; and
- (vi) the Company announcing whether and when it had applied to the Accounting and Corporate Regulatory Authority for the Waiver and the outcome of its application.

Grounds for the Extensions

Please refer to the Announcement for the grounds for seeking the Extensions.

Satisfaction of the Waiver's Conditions

Following this announcement on the Waiver granted and the Announcement, which sets out, *inter alia*, the Company's grounds for seeking the Waiver, the Company has fulfilled the Waiver's condition (i) above.

The Company confirms that it is not aware of any information that will have a material bearing on investors' decision which has yet to be announced by the Company.

The Company confirms that the Waiver will not contravene any laws and regulations governing the Company or its Constitution and will make an immediate disclosure via SGXNet if such contravention arises.

The Company will make update announcements when the rest of the Waiver's conditions is satisfied.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
18 September 2024

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.